Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS) is a chronic condition without a diagnostic test and some 80 - 90% of patients remain un-diagnosed. A new paper published in Frontiers in Medicine outlines how having a diagnostic test could greatly help both patients and medics.

Biomarker illustration with text 'Propelling research, providing hope, preserving dignity'

ME/CFS is a devastating disease that affects over 250,0001 individuals in the UK, yet there is no reliable biomarker and diagnosis is based on manifesting clinical symptoms, coupled with high inter-patient variability. 

Developing an early diagnostic test is of fundamental importance in the treatment of any illness. In ME/CFS a diagnostic test would help not only in the clinical management of patients and but give patients hope that we are moving closer to understanding a condition which is currently is very much a mystery illness.

Using modern statistical approaches and machine learning Dr Karl Morten (Nuffield Department of Women's and Reproductive Health) and his colleagues have identified a series of variables including the micro RNA’s of blood cells and small extracellular vesicles which can distinguish a group of severe ME/CFS patients from healthy controls with 100% accuracy. These two groups cannot be readily separated by a standard blood test. Standard tests return as negative for the severely ill group. Their next step is to apply this approach to mild and moderately affected ME/CFS patients with different levels of disability and compare to other disease groups as well as healthy controls. This will determine if we have a potential panel of biomarkers which could be used to developed a diagnostic test. 

Read the full story on the Nuffield Department of Women's and Reproductive Health website

 

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.